Parkinson's Patients Have Improved Motor and Non-Motor Function After Treatment with Theralase(R) Cool Laser TherapyToronto, ...

A recently launched Phase 1 clinical trial is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem cells are reprogrammed to ...

A recently launched Phase 1 clinical trial at Mass General Brigham is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem ...

Cell replacement for Parkinson’s disease replaces the dopamine neurons lost to degeneration and can restore dopaminergic function in the brain, providing a completely new treatment modality ...

Professor Lezanne Ooi awarded close to $400k for new study to understand links between environmental toxins and debilitating ...

Parkinson’s disease (PD) affects nearly 2% of adults over 65, making it the second most common neurodegenerative disorder. It ...

The nervous system is a major target for both positive and negative actions of hormones while using hormonal contraceptives.

Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the ...

Parkinson’s disease is a neurodegenerative disorder that affects millions of people worldwide, causing a range of motor and ...

The start of trials is a milestone for Bayer's ambition to develop cell and gene-based therapies for Parkinson's that could replace the dopamine-producing neurons ... take full control of BlueRock ...